How to gain a competitive advantage in a fast-changing pharmaceutical supply ecosystem.
The global Covid-19 pandemic as well as geopolitical tensions and trade restrictions have drawn attention to profound geographical, technical, and structural shifts in pharmaceutical supply chains. Treatments are increasingly produced by highly capable contract development and manufacturing organizations (CDMOs). As new, extraordinarily sophisticated, advanced therapies (ATx) emerge to complement traditional large and small molecule treatments, this trend looks set to deepen and accelerate. Today, CDMOs are targeting an increasingly attractive business segment, in which pure play CDMOs and other market participants are taking on a growing role.
For the 2022 Global CDMO Study, Strategy& Germany put together data from 150 of the world’s major players, classified according to the nature of their core business: pure play CDMO, PharmaCo CDMO, generics manufacturing CDMO, and pharma affiliate CDMO.
This study provides you with vital insights into the routes to competitive advantages, especially for marketing authorization holders (MAHs) that are set up to collaborate with CDMOs, for CDMOs positioned to serve marketing authorization holders, and for others that aspire to closer commercial relationships.
The Six Key findings:
1) MAHs are expanding strategic collaborations with CDMOs
2) CDMO management is being more and more professionalized to ensure mutual success
3) MAHs increasingly also act as CDMOs, offering spare capacity to the market to absorb costs
4) CDMOs are continuously expanding their service portfolio towards end-to end service providers
5) CDMOs are expanding beyond traditional technology portfolios
6) CDMOs are producing advanced therapies, turning visionary hype into operational reality
You can access the full study below.
We would be delighted to further discuss with you.
Dr. Sandra Ragaz, Partner
Leader Pharma & Life Science VAT Switzerland
Tel: +41 58 792 44 69
Dr. Jens Neumann, Partner
PwC Strategy& Germany